Research, Collaboration and Licensing Agreements - Schedule of Revenue Recognized from Strategic Partnerships (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 4,590	$ 48,726	$ 6,998	$ 75,836
Jazz: \| Development support payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	291	475	683	4,968
Jazz: \| Drug supply for ongoing studies
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	791	1,841	1,136	4,798
Jazz: \| Other drug supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	45	0	162	2,150
Jazz: \| Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	1,589	550	2,919	752
BeOne: \| Other drug supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	1,664	7	1,664	215
BeOne: \| Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	210	19	434	19
BeOne: \| Milestone revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	20,000	0	20,000
BeOne: \| Recognition of deferred revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	18,334	0	18,334
Bristol-Myers Squibb Company \| Option exercise fee
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	7,500	0	7,500
GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”): \| Milestone revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	0	0	14,000
Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”): \| Milestone revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 0	$ 0	$ 0	$ 3,100